Resveratrol, piceatannol and analogues demonstrate a high potency both as inhibitors of androgen synthesis and androgen receptor activation, according to a study, suggesting the potential of such compounds in the chemoprevention of prostate cancer.
In patients with renal cell carcinoma, mean platelet volume is a highly significant risk factor for recurrence and cancer-specific death, a recent study has found. This parameter enhances the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases following curative surgical resection.
Severity of malignancy, preoperative serum albumin concentration, intraoperative blood loss and duration of operation, among other factors, predict postoperative pneumonia (POP) development following major oral cancer (OC) surgery, a recent study has found.
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
The minimal clinically important difference (MCID) of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Asian breast cancer patients ranges from 4.50 to 10.79 points, a recent study from Singapore reveals.
Family history of melanoma and CDKN2A mutation status significantly affect the risks of developing subsequent melanomas and other cancers and survival outcomes in patients with multiple primary melanomas (MPMs), a recent study has shown.
In patients infected with Helicobacter pylori, long-term use of proton pump inhibitors is associated with an increased risk of gastric cancer even after treatment for the infection, a recent population-based study has shown.
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.